Is MDT a Buy? What to Consider in 2026
Last updated June 2026
Short answer
There is no universal answer to whether MDT is a buy; it depends on your thesis, time horizon, and what you already own. Below is the case for Medtronic, the main risks to weigh, where the stock trades, and a framework to decide for yourself. This is informational, not a recommendation, and Walnut is not an investment adviser.
Medtronic is one of the largest medical device companies in the world, designing, manufacturing, and selling therapies and devices across a broad range of chronic and acute conditions. Its business spans four main areas: Cardiovascular (pacemakers, defibrillators, heart valves, and cardiac ablation), Neuroscience (spine implants, neuromodulation for pain and movement disorders, and surgical navigation), Medical Surgical (surgical stapling, energy devices, and a growing robotic-surgery platform), and Diabetes (insulin pumps and continuous glucose monitoring). The company sells primarily to hospitals, surgeons, and health systems, generating durable, recurring demand tied to procedure volumes and chronic-disease management. Medtronic's scale gives it deep relationships with providers, a large installed base of devices, and the resources to fund extensive R&D and acquisitions. Growth depends on new product cycles, pipeline approvals, and global expansion, especially in emerging markets. Founded in 1949 and headquartered in Ireland for tax purposes (operationally rooted in Minnesota), Medtronic is a large-cap, dividend-growing medical-technology company tied to long-term healthcare demand and aging demographics.
The case for Medtronic
1. Diversified device portfolio.
Medtronic spans cardiovascular, neuroscience, medical surgical, and diabetes, so no single product or therapy dominates results. This breadth smooths revenue across product cycles and reimbursement changes, and the large installed base of implanted devices and capital equipment creates recurring demand for replacements, consumables, and follow-on procedures across health systems worldwide.
2. Innovation pipeline and new product cycles.
Growth is driven by new approvals and product cycles: pulsed-field ablation for atrial fibrillation, next-generation insulin pumps and continuous glucose monitoring, and the Hugo robotic-surgery system competing in soft-tissue robotics. A strong cadence of pipeline launches can reaccelerate growth in segments that had matured, and Medtronic's R&D scale supports a steady flow of new therapies.
3. Aging demographics and chronic disease.
Long-term demand for cardiac, spine, diabetes, and neurological therapies rises with aging populations and the growing prevalence of chronic disease. As a market leader, Medtronic is positioned to benefit from secular increases in procedure volumes, particularly as healthcare access expands in emerging markets.
4. Dividend growth and cash generation.
Medtronic is a Dividend Aristocrat with decades of consecutive increases, supported by steady cash flow from its diversified device base. This makes it a defensive, income-oriented holding within healthcare, with capital returned through dividends and buybacks alongside reinvestment and bolt-on acquisitions.
The risks to weigh
Medtronic has at times delivered sluggish organic growth, raising concerns that its scale slows innovation relative to nimbler competitors like Boston Scientific and Edwards Lifesciences. The Hugo robotic platform faces an entrenched Intuitive Surgical, and the diabetes business has battled competitive pressure and prior regulatory issues. Device companies face reimbursement pressure, hospital budget constraints, FDA approval and recall risk, and litigation exposure. A large international footprint brings currency headwinds. The valuation is moderate but the stock has lagged when growth disappointed. New-product execution, pipeline timing, and the ability to reaccelerate organic growth remain the key swing factors for the investment case.
Valuation context (as of early 2026)
- Revenue (TTM): ~$33 billion
- Operating margin: ~20% (non-GAAP higher; GAAP affected by amortization)
- Net income (TTM): ~$4.5 billion
- EPS (TTM): ~$3.50 GAAP; non-GAAP higher
- P/E (TTM): ~17x on non-GAAP earnings
- Dividend yield: ~3.0%, a Dividend Aristocrat with decades of increases
- Free cash flow: ~$5 billion annually
- Segment mix: Cardiovascular largest, plus Neuroscience, Medical Surgical, and Diabetes
Medtronic trades at a moderate valuation relative to faster-growing medtech peers, reflecting its scale, diversification, and reliable dividend but also a track record of slower organic growth. The multiple has expanded when new product cycles reaccelerated growth and compressed during periods of execution stumbles. The yield gives it a defensive, income-oriented profile within healthcare.
How to decide for yourself
Rather than asking whether MDT is a buy in the abstract, it tends to help to answer four questions:
- Thesis: do you believe the case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold MDT indirectly through an index or sector ETF before adding more.
For the full picture, see the MDT stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about MDT against your real portfolio and see your actual exposure before deciding.
Build a basket around MDT with Walnut
Use Medtronic as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
Is MDT a good stock to buy right now?
+
There is no universal answer. Whether Medtronic fits depends on your thesis, time horizon, risk tolerance, and what you already own. This page lays out the case for, the main risks, and where the stock trades, so you can decide for yourself. Walnut is not an investment adviser and this is not a recommendation.
What does Medtronic do?
+
One of the largest medical device makers; diversified across cardiac, neuro, surgical, and diabetes; Dividend Aristocrat.
What are the main risks of MDT?
+
Medtronic has at times delivered sluggish organic growth, raising concerns that its scale slows innovation relative to nimbler competitors like Boston Scientific and Edwards Lifesciences. The Hugo robotic platform faces an entrenched Intuitive Surgical, and the diabetes business has battled competitive pressure and prior regulatory issues. Device companies face reimbursement pressure, hospital budget constraints, FDA approval and recall risk, and litigation exposure. A large international footprint brings currency headwinds. The valuation is moderate but the stock has lagged when growth disappointed. New-product execution, pipeline timing, and the ability to reaccelerate organic growth remain the key swing factors for the investment case.
What is Medtronic's ticker symbol?
+
MDT, listed on the New York Stock Exchange. Officially Medtronic plc. Founded in 1949, operationally rooted in Minnesota with legal domicile in Ireland. Trades during US market hours and is available at every major US brokerage.
What does Medtronic do?
+
Medtronic is one of the world's largest medical device companies. It makes therapies and devices across cardiovascular (pacemakers, defibrillators, heart valves, ablation), neuroscience (spine, neuromodulation), medical surgical (stapling, energy, robotic surgery), and diabetes (insulin pumps, glucose monitoring), selling mainly to hospitals and surgeons.
Who are Medtronic's main competitors?
+
Boston Scientific, Abbott, and Edwards Lifesciences in cardiovascular; Intuitive Surgical, Johnson & Johnson, and Stryker in surgical and robotics; Abbott, Dexcom, and Insulet in diabetes. Medtronic competes on scale and breadth across these therapy areas.
Does Medtronic pay a dividend?
+
Yes. Medtronic is a Dividend Aristocrat with decades of consecutive annual increases, yielding roughly 3.0% as of early 2026. Steady cash flow from its diversified device portfolio supports the dividend alongside buybacks and reinvestment, giving it a defensive, income-oriented profile within healthcare.
Walnut is informational and is not an investment adviser. This page is educational and not a recommendation to buy or sell MDT; figures are approximate and dated, and your own situation, time horizon, and risk tolerance should drive any decision. Verify current data before investing.